Clinical Trial Update: Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis [Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 2 study evaluating subcutaneous daclizumab in patients with active, relapsing forms of multiple scl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Daclizumab (daclizumab)

Snippet

Sponsor: PDL BioPharma, Inc. | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED